Merck KGaA Receives FDA Approval for TGCT Treatment, Pimjetmi

Merck KGaA has received U.S. Food and Drug Administration (FDA) approval for Pimjetmi, a new once-daily oral treatment for symptomatic tenosynovial giant cell tumor (TGCT), a rare bone tumor. The approval marks a significant advancement for patients with this condition, offering a systemic treatment option where previously limited choices existed.

The FDA’s decision is based on positive data from the Phase 3 MANEUVER study, which demonstrated early and sustained tumor response with clinically meaningful improvements in all efficacy assessments, including physical function and pain. The study also highlighted a high objective response rate (ORR) alongside a manageable safety profile for Pimjetmi, indicating its potential as a well-tolerated treatment option. This data is critical, as TGCT can cause significant pain and disability, and current treatments often involve surgery or localized therapies.

While the filing does not detail projected peak sales or market share for Pimjetmi, the FDA approval represents a key milestone for Merck’s oncology pipeline. The successful Phase 3 trial and subsequent approval validate the company’s investment in targeted therapies for rare cancers, and position Pimjetmi as a potential new standard of care for eligible TGCT patients. The approval’s impact on Merck’s future revenue will depend on uptake and competition within the TGCT treatment landscape.